Research programme: serotonin 4 receptor agonists - Suven Life Sciences

Drug Profile

Research programme: serotonin 4 receptor agonists - Suven Life Sciences

Alternative Names: SUVN-D1003019

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suven Life Sciences
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 21 Jul 2017 Suven Life Sciences receives patent for serotonin 4 compounds in Australia
  • 13 Jun 2017 Suven Life Sciences receives patent allowance for its Serotonin 4 receptor agonists in the US and Australia
  • 28 Mar 2017 Suven Life Sciences has patent protection for chemical entities covering the class of selective 5-HT4 compounds for the treatment of neurodegenerative disorders in New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top